Olympus Corporation

Corporate brand

Japanese medical-technology company and former optical-imaging brand, best known for gastrointestinal endoscopy and surgical visualization systems.

Last updated October 13, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Olympus Corporation is a Japanese precision-technology company whose modern business is centered on medical devices, particularly gastrointestinal endoscopy, surgical endoscopy, therapeutic endoscopy and related minimally invasive technologies. It was founded in Tokyo in 1919 as Takachiho Seisakusho by Takeshi Yamashita. The company initially produced microscopes and thermometers, later expanding into cameras, lenses, scientific instruments, audio recorders and industrial inspection equipment. The Olympus name was registered as a trademark in 1921 and became the foundation of a globally recognized optical brand. The company's historical identity was strongly shaped by consumer imaging. Olympus introduced the Semi-Olympus I camera in 1936 and developed the compact Pen half-frame camera from 1959. Its OM 35 mm single-lens-reflex system, created by a design group led by Yoshihisa Maitani, became known for compact bodies, small lenses and advanced metering. Olympus later helped develop the Four Thirds and Micro Four Thirds standards with Panasonic, producing the PEN and OM-D mirrorless camera families. It also sold voice recorders, including microcassette products, and built a substantial scientific-imaging and microscopy business. Medical technology gradually became the company's strategic core. Olympus developed flexible endoscopy capabilities and expanded through products for gastrointestinal diagnosis, surgical visualization, ultrasound, electrosurgery, endotherapy, cleaning and disinfection. Its endoscopes became widely used in hospitals and clinics internationally, giving the company a leading position in the global gastrointestinal endoscopy market. Partnerships with Sony supported high-resolution, three-dimensional and specialized surgical endoscopy systems, including the VISERA 4K UHD and VISERA ELITE III platforms. Olympus also expanded in urology through the acquisition of Medi-Tate and its iTind temporary implant for symptoms associated with benign prostatic hyperplasia. Olympus suffered a major governance and financial crisis in 2011 after chief executive Michael Woodford questioned large advisory payments and acquisitions that had been used to conceal investment losses. His dismissal triggered international scrutiny, investigations, arrests and extensive restructuring. The company later paid substantial penalties related to a long-running accounting and kickback scheme and strengthened governance and compliance systems. The company subsequently exited businesses that were no longer central to its medical strategy. Its imaging division was transferred to OM Digital Solutions, backed by Japan Industrial Partners, in 2020. The scientific-imaging and microscopy business was rebranded as Evident and sold to Bain Capital in 2023. As of 2025, Olympus is principally a medical-technology company rather than a camera, audio or general scientific-instrument manufacturer. Its present portfolio is focused on endoscopy and surgical technologies, supported by a worldwide commercial and service network. Olympus Corporation is a Japanese global medical-technology company headquartered in Hachioji, Tokyo. Established in 1919 as Takachiho Manufacturing Company, it began with the domestic production of microscopes and other optical instruments. The company adopted the Olympus name in 1949 and subsequently developed businesses spanning cameras, lenses, microscopes, industrial inspection equipment, medical instruments, and consumer recording products. Olympus became especially influential in medical visualization. Its early medical work included the production of medical equipment from 1952, followed by sustained development of gastrocameras, flexible endoscopes, imaging systems, electrosurgical devices, and therapeutic accessories. The company’s endoscopy business grew from optical engineering into a broad clinical platform combining scopes, processors, light sources, image enhancement, treatment devices, and associated services. Gastrointestinal endoscopy has remained the company’s defining franchise and a central part of its global identity. For much of the twentieth and early twenty-first centuries, Olympus operated as a diversified precision-technology group. Its imaging business used the Olympus, OM-D, and PEN brands and helped popularize compact interchangeable-lens cameras. The 2009 PEN E-P1, based on the Micro Four Thirds standard developed with Panasonic, was positioned as a smaller alternative to conventional digital single-lens reflex cameras and attracted both enthusiast photographers and consumers seeking portable, high-quality equipment. Olympus also sold voice recorders, microscopes, industrial microscopes, nondestructive-testing equipment, and scientific instruments. The group’s strategic direction changed substantially after the accounting scandal that emerged in 2011. Following governance and financial-reporting turmoil, Olympus undertook restructuring, strengthened oversight, and increasingly concentrated capital on medical technology. Its later transformation included the transfer of the imaging business to OM Digital Solutions in 2021 and the separation of the scientific business, whose life-science and industrial activities were transferred to Evident from 2022. These transactions marked a transition from a diversified optical manufacturer to a more focused medtech company. Olympus now emphasizes early detection, diagnosis, and minimally invasive treatment. Its principal activities cover gastrointestinal and respiratory endoscopy, surgical energy, visualization, urology, respiratory care, and therapeutic devices. The company supplements internal research and development with acquisitions intended to add specialized technologies and expand clinical portfolios. Acquisitions and investments during the 2020s included respiratory endoscopy capabilities, fluorescence imaging, urology technologies, and gastrointestinal treatment devices. The company’s stated purpose is to contribute to the health, safety, and wellbeing of people worldwide. In 2018 it redefined its global corporate philosophy around Our Purpose and five core values: integrity, empathy, long-term view, agility, and unity. The reform was intended to create a common basis for decision-making across regions and businesses. Olympus’s current positioning is therefore less about consumer optics than about clinically integrated medtech solutions delivered through relationships with physicians, hospitals, distributors, and healthcare systems worldwide. Olympus Corporation is a Japanese global medical-technology company headquartered in Hachioji, Tokyo. It was founded in Tokyo on 12 October 1919 as Takachiho Seisakusho (Takachiho Manufacturing Company) by Takeshi Yamashita, initially producing microscopes and thermometers to reduce Japan's dependence on imported precision equipment. The Olympus trademark was registered in 1921, referring both to Mount Olympus in Greek mythology and to the company's earlier association with Mount Takachiho. The corporate name changed to Takachiho Optical Industries in 1942 and to Olympus Optical Co., Ltd. in 1949, the same year it listed on the Tokyo Stock Exchange. The company adopted its current name, Olympus Corporation, in 2003. Olympus broadened its optical portfolio over the twentieth century. It introduced the Semi-Olympus I camera in 1936, its first camera, using a Zuiko-branded lens, and later produced the Chrome Six folding camera. The Pen series, launched in 1959, used a half-frame format that allowed many more exposures from standard 35 mm film and established Olympus as a designer of small, portable cameras. The OM 35 mm single-lens-reflex system, created by a design group led by Yoshihisa Maitani, became known for compact bodies, small lenses and advanced metering such as through-the-lens and off-the-film metering. Olympus later helped develop the Four Thirds and Micro Four Thirds standards with Panasonic, producing the PEN and OM-D mirrorless camera families; the 2009 PEN E-P1 was positioned as a smaller alternative to conventional digital single-lens reflex cameras. It also sold voice recorders, including microcassette products, and built a substantial scientific-imaging and microscopy business. In 2011, after CEO Michael Woodford questioned unusually large advisory payments and acquisition-related transactions, Olympus dismissed him. Investigations found that the company had concealed investment losses through complex arrangements. The affair led to arrests, criminal proceedings, management changes, investor scrutiny and extensive governance reform. Olympus later paid approximately US$646 million in fines related to the illegal accounting and kickback scheme. The company subsequently exited businesses no longer central to its medical strategy. Its imaging division was transferred to OM Digital Solutions in 2020, backed by Japan Industrial Partners. The scientific-imaging and microscopy business was rebranded Evident and sold to Bain Capital in 2023. Leadership also changed during the transformation: Yasuo Takeuchi handed the CEO role to Stefan Kaufmann in April 2023 and became chair and ESG officer; Kaufmann's tenure ended in 2024; and Bob White became president and CEO in June 2025. As of 2025, Olympus is principally a medical-technology company rather than a camera, audio or general scientific-instrument manufacturer, with a portfolio focused on endoscopy and surgical technology supported by a global commercial and service network.

History

Olympus was established on 12 October 1919 as Takachiho Seisakusho. Its early products were microscopes and thermometers, reflecting the company's original ambition to manufacture precision optical instruments in Japan. The Olympus trademark was registered in 1921. The name referred both to Mount Olympus in Greek mythology and, conceptually, to the Japanese company's earlier association with Mount Takachiho. The corporate name changed to Takachiho Optical Industries in 1942 and to Olympus Optical Co., Ltd. in 1949. During the postwar period, Olympus broadened its optical portfolio. It introduced the Semi-Olympus I camera in 1936 and later produced the Chrome Six folding camera. The Pen series, launched in 1959, used a half-frame format that allowed many more exposures from standard 35 mm film and established Olympus as a designer of small, portable cameras. The company became especially influential in professional photography through the OM system. Led by Yoshihisa Maitani, the design team made 35 mm SLR bodies and lenses substantially smaller than many competing systems while retaining advanced features such as through-the-lens and off-the-film metering. Olympus subsequently developed digital cameras, the Four Thirds standard and, with Panasonic, the Micro Four Thirds mirrorless system. PEN and OM-D cameras extended the company's design language into the digital era. Alongside consumer imaging, Olympus expanded its microscope, industrial inspection and audio-recorder activities. Medical optics became increasingly important. Olympus developed flexible endoscopy and built a broad platform covering gastrointestinal examination, surgical visualization, therapeutic instruments, electrosurgery, ultrasound and reprocessing equipment. The acquisition of KeyMed in 1987 strengthened its medical and industrial equipment operations in Europe. Olympus's reputation was severely damaged in 2011. Newly appointed chief executive Michael Woodford investigated payments associated with acquisitions and advisory arrangements and was dismissed after raising concerns. Subsequent investigations found that losses had been concealed through complex transactions. Several individuals were arrested or prosecuted, and Olympus paid major fines connected with the accounting and kickback matters. The episode led to changes in management, board oversight, disclosure and compliance. After the scandal, Olympus increasingly prioritized medical technology. It formed a medical partnership with Sony in 2012, commercialized 4K surgical endoscopy systems, acquired Medi-Tate in 2021 and continued developing therapeutic and urological devices. At the same time, it separated non-core businesses. The imaging operation was transferred to OM Digital Solutions in 2020, while the scientific-imaging business became Evident and was sold to Bain Capital in 2023. Olympus is now principally an international endoscopy and surgical-technology company. Olympus was founded in October 1919 in Tokyo as Takachiho Manufacturing Company. Its original purpose was to produce microscopes and other optical instruments domestically, at a time when Japan depended heavily on imported precision equipment. The company changed its name to Takachiho Optical Industry in 1942 and to Olympus Optical Company in 1949. It was listed on the Tokyo Stock Exchange in May 1949. The company began manufacturing medical equipment in 1952 and expanded its optical expertise into clinical applications. Medical imaging became a long-term strategic foundation, particularly after Olympus developed increasingly practical gastrocameras and flexible endoscopy technologies. During the postwar decades, Olympus also entered cameras, measuring instruments, microscopes, and other precision products. Its camera business helped establish the PEN name, while its microscope and industrial businesses extended the brand beyond healthcare. Olympus continued to internationalize during the 1960s, establishing a European operating base in 1964 and later building regional organizations across Asia-Pacific and other markets. Its medical business broadened through internal development and acquisitions. The 2008 acquisition of Gyrus Group strengthened its surgical business, adding technologies and products relevant to minimally invasive procedures. In the 2000s, Olympus reorganized several activities into separate operating companies while retaining a diversified group structure. It changed its corporate name to Olympus Corporation in 2003. Imaging products remained visible to consumers, while medical and scientific operations became increasingly important to the company’s long-term economics. A major crisis emerged in 2011 when former executive Michael Woodford raised concerns about unusual acquisitions and payments. Investigations uncovered extensive accounting irregularities and concealed investment losses. The scandal led to the resignation of senior executives, legal and regulatory consequences, and a severe loss of investor confidence. Olympus subsequently pursued governance reform, strengthened its board and oversight systems, and sought to restore its financial credibility. The post-2011 period brought a sharper focus on medical technology. Olympus acquired additional surgical and visualization capabilities, including Gyrus-related operations and later technologies in fluorescence imaging, respiratory endoscopy, urology, and gastrointestinal intervention. In 2018 the company revised its corporate philosophy around a common global purpose and five core values. The initiative supported a broader transformation program aimed at becoming a truly global medtech company. Olympus sold its imaging business to a private-equity-backed structure in 2021, transferring the camera operations to OM Digital Solutions. The same period also saw acquisitions such as Quest Photonic Devices for fluorescence imaging and Medi-Tate for urology. Olympus then transferred its scientific and industrial businesses to Evident in April 2022. These changes removed most of the group’s former consumer and general-purpose optical activities and concentrated resources on medical care. Leadership also changed during the transformation. Yasuo Takeuchi, who had led the restructuring and medical focus, handed the CEO role to Stefan Kaufmann in April 2023 and became chair and ESG officer. Kaufmann’s tenure ended in 2024, after which interim leadership arrangements were reported. Bob White became president and CEO in June 2025 according to the company’s published management information. Today Olympus is principally a medtech company. Its core business centers on endoscopy, surgical intervention, urology, respiratory care, visualization, and treatment devices. The company continues to use acquisitions, venture investment, research, and partnerships to add capabilities around disease detection and minimally invasive therapy. Its historical identity as an optical and imaging manufacturer remains important to the brand, but its present commercial and strategic identity is overwhelmingly medical. Olympus was established on 12 October 1919 in Tokyo as Takachiho Seisakusho (Takachiho Manufacturing Company). Its original purpose was to produce microscopes and other optical instruments domestically, at a time when Japan depended heavily on imported precision equipment. The Olympus trademark was registered in 1921; the name referred both to Mount Olympus in Greek mythology and, conceptually, to the company's earlier association with Mount Takachiho. The corporate name changed to Takachiho Optical Industries in 1942 and to Olympus Optical Co., Ltd. in 1949, the same year the company was listed on the Tokyo Stock Exchange. During the postwar period, Olympus broadened its optical portfolio. It introduced the Semi-Olympus I camera in 1936, its first camera, which used a Zuiko-branded lens, and later produced the Chrome Six folding camera. The Pen series, launched in 1959, used a half-frame format that allowed many more exposures from standard 35 mm film and established Olympus as a designer of small, portable cameras. The company became especially influential in professional photography through the OM system. Led by Yoshihisa Maitani, the design team made 35 mm SLR bodies and lenses substantially smaller than many competing systems while retaining advanced features such as through-the-lens and off-the-film metering. Olympus subsequently developed digital cameras, the Four Thirds standard and, with Panasonic, the Micro Four Thirds mirrorless system. PEN and OM-D cameras extended the company's design language into the digital era; the 2009 PEN E-P1 was positioned as a smaller alternative to conventional digital single-lens reflex cameras. Alongside consumer imaging, Olympus expanded its microscope, industrial inspection and audio-recorder activities. The company began manufacturing medical equipment in 1952 and expanded its optical expertise into clinical applications. Medical imaging became a long-term strategic foundation, particularly after Olympus developed increasingly practical gastrocameras and flexible endoscopy technologies. It built a broad platform covering gastrointestinal examination, surgical visualization, therapeutic instruments, electrosurgery, ultrasound and reprocessing equipment. The acquisition of KeyMed in 1987 strengthened its medical and industrial equipment operations in Europe. Olympus continued to internationalize during the 1960s, establishing a European operating base in 1964 and later building regional organizations across Asia-Pacific and other markets. The 2008 acquisition of Gyrus Group strengthened its surgical business, adding technologies and products relevant to minimally invasive procedures. In the 2000s, Olympus reorganized several activities into separate operating companies while retaining a diversified group structure, and changed its corporate name to Olympus Corporation in 2003. After the scandal, Olympus increasingly prioritized medical technology. It formed a medical partnership with Sony in 2012, commercialized 4K surgical endoscopy systems, acquired Medi-Tate in 2021 and continued developing therapeutic and urological devices. In 2018 the company revised its corporate philosophy around a common global purpose and five core values, supporting a broader transformation program aimed at becoming a truly global medtech company. At the same time, it separated non-core businesses. The imaging operation was transferred to OM Digital Solutions in 2020, while the scientific-imaging business became Evident and was sold to Bain Capital in 2023. Leadership also changed during the transformation: Yasuo Takeuchi, who had led the restructuring and medical focus, handed the CEO role to Stefan Kaufmann in April 2023 and became chair and ESG officer; Kaufmann's tenure ended in 2024, after which interim leadership arrangements were reported; and Bob White became president and CEO in June 2025 according to the company's published management information. Olympus is now principally an international endoscopy and surgical-technology company.

2025
Bob White becomes president and CEO
[7]Olympus corporate officer informationolympus.co.jp
Company management information identifies Bob White as representative executive officer, president, and CEO from June 2025.
2023
Evident divested
[5]Olympus Evident divestment announcementolympus-global.com
The scientific-imaging and microscopy business was sold to Bain Capital.
2023
Evident divested and Kaufmann becomes president and CEO
[9]Olympus announces CEO successionolympus.co.jp
The scientific-imaging and microscopy business was sold to Bain Capital, and Stefan Kaufmann succeeded Yasuo Takeuchi as president and CEO during the medtech transformation.
2022
Scientific business transferred to Evident
[11]Olympus Marketing business overviewolympus-marketing.co.jp
Life-science and industrial equipment activities were transferred to Evident, further narrowing Olympus's operating focus.
2021
Transfers imaging business to OM Digital Solutions
[8]Olympus annual report and corporate historyolympus.co.jp
The camera and imaging business was transferred to OM Digital Solutions as Olympus concentrated on medical technology.
2020
Imaging business transferred to OM Digital Solutions
[3]Olympus imaging business transfer announcementolympus-global.com
Olympus separated its camera and audio operation from the parent company's medical strategy, with Japan Industrial Partners as controlling backer.
2018
Revises global corporate philosophy
[10]Olympus new corporate philosophy and internal rolloutsendenkaigi.com
Olympus introduced a common purpose focused on health, safety, and wellbeing, supported by five global core values.
2012
Sony medical joint venture announced
[1]Olympus Corporationen.wikipedia.org
Olympus and Sony established a partnership for advanced surgical endoscopy.
2011
Accounting scandal becomes public
[1]Olympus Corporationen.wikipedia.org
The dismissal of Michael Woodford exposed concealed losses and triggered investigations, arrests, fines and governance reforms.
2011
Accounting scandal and governance crisis
[1]Olympus Corporationen.wikipedia.org
The exposure of concealed investment losses and irregular payments triggered executive changes, investigations, and a major governance reform effort.
2008
Acquires Gyrus Group
[8]Olympus annual report and corporate historyolympus.co.jp
The acquisition strengthened Olympus's surgical and minimally invasive medical-device activities.
2003
Company adopts current corporate name
[1]Olympus Corporationen.wikipedia.org
Olympus Optical Co., Ltd. became Olympus Corporation.
2003
Renamed Olympus Corporation
[8]Olympus annual report and corporate historyolympus.co.jp
The corporate name changed from Olympus Optical Company to Olympus Corporation.
1987
KeyMed acquired
[1]Olympus Corporationen.wikipedia.org
The acquisition strengthened Olympus's medical and industrial equipment presence in Europe.
1959
Pen camera launched
[1]Olympus Corporationen.wikipedia.org
The half-frame Pen established a compact-camera design tradition that became central to Olympus imaging.
1952
Begins medical-equipment manufacturing
[8]Olympus annual report and corporate historyolympus.co.jp
Olympus formally entered medical equipment manufacturing, establishing the foundation for its later medtech specialization.
1949
Adopts the Olympus Optical name and lists in Tokyo
[8]Olympus annual report and corporate historyolympus.co.jp
The company became Olympus Optical Co., Ltd. and was listed on the Tokyo Stock Exchange.
1936
First Olympus camera introduced
[1]Olympus Corporationen.wikipedia.org
The Semi-Olympus I became the company's first camera and used a Zuiko-branded lens, broadening its optical-technology business beyond microscopes.
1936
Enters camera manufacturing
[8]Olympus annual report and corporate historyolympus.co.jp
Olympus began producing cameras, broadening its optical-technology business beyond microscopes.
1921
Olympus trademark registered
[1]Olympus Corporationen.wikipedia.org
The Olympus name was adopted for microscopes and other optical products, referring both to Mount Olympus in Greek mythology and to Mount Takachiho.
1919
Company founded as Takachiho Seisakusho
[1]Olympus Corporationen.wikipedia.org
Takeshi Yamashita established the company in Tokyo to manufacture microscopes and other precision optical products, reducing Japan's dependence on imported equipment.

Products and positioning

A specialist, high-end medical-technology brand focused on minimally invasive diagnosis, visualization and treatment, with a legacy in precision optics and imaging. A global medtech specialist focused on early detection, diagnosis, and minimally invasive treatment, with gastrointestinal endoscopy as its core franchise.

Medical devices
Gastrointestinal endoscopy systems
Olympus's core product family includes flexible endoscopes, processors, visualization systems and therapeutic accessories for gastrointestinal diagnosis and treatment. The portfolio supports procedures such as upper gastrointestinal examination and colonoscopy, and is sold through hospitals and clinical-care networks worldwide. Olympus began manufacturing medical equipment in 1952 and developed increasingly practical gastrocameras and flexible endoscopy technologies.
Surgical endoscopy · 2015
VISERA 4K UHD
A high-resolution surgical endoscopy platform developed through the Olympus-Sony medical partnership. It was designed to provide 4K visualization for operating-room procedures and formed part of Olympus's move toward advanced digital surgical imaging.
Surgical endoscopy · 2022
VISERA ELITE III
An advanced surgical endoscopy system incorporating 4K imaging and specialized capabilities including infrared and narrow-band imaging. Olympus introduced it in selected European, Middle Eastern, African and Asia-Pacific markets in 2022.
Urology
iTind
A temporarily implanted nitinol device developed by Medi-Tate for minimally invasive treatment of lower urinary-tract symptoms associated with benign prostatic hyperplasia. It is designed to reshape portions of the prostatic urethra and bladder neck during a temporary treatment period.
Former imaging products · 2009
OM-D and PEN cameras
Olympus's digital interchangeable-lens camera families used the Micro Four Thirds format. PEN cameras continued the company's compact design heritage, while OM-D models combined mirrorless imaging with electronic viewfinders and styling inspired by the earlier OM film system. The PEN E-P1 helped establish compact Micro Four Thirds cameras as an alternative to larger DSLR equipment. The business was transferred to OM Digital Solutions in 2020. PEN and OM-D were major Olympus interchangeable-lens camera lines. The PEN E-P1 helped establish compact Micro Four Thirds cameras as an alternative to larger DSLR equipment. Olympus later transferred the imaging business to OM Digital Solutions, so these products are no longer part of Olympus Corporation’s current operating portfolio.
Former scientific imaging products
Olympus microscopes
Olympus historically supplied microscopes for education, routine laboratory work, life-science research and materials analysis. This scientific-imaging operation was rebranded Evident and sold to Bain Capital in 2023.
Gastrointestinal endoscopy system · 2020
EVIS X1
EVIS X1 is Olympus’s flagship gastrointestinal endoscopy platform. It combines endoscopes, processors, light sources, image-enhancement technologies, and compatible therapeutic tools to support examination and treatment. The platform reflects Olympus’s strategy of integrating visualization and intervention rather than selling scopes as isolated optical products.
Medical endoscopy · 1952
Gastrointestinal endoscopes
Olympus gastrointestinal endoscopes are used for procedures involving the upper and lower digestive tract. The portfolio includes flexible scopes, imaging processors, accessories, and treatment instruments designed to support screening, diagnosis, tissue sampling, hemostasis, resection, and other minimally invasive interventions.
Surgical equipment · 2008
Surgical visualization and energy systems
This portfolio includes laparoscopic and endoscopic visualization products, surgical cameras, image-management technologies, electrosurgical generators, and energy instruments. These systems are used to improve visualization and enable tissue cutting, coagulation, and other minimally invasive surgical techniques.
Urology devices · 2021
Urology products
Olympus's urology portfolio includes endoscopes and treatment technologies for urinary-tract procedures, including products for kidney and ureter access and stone management. Acquisitions in the 2020s expanded the company's capabilities in urological diagnosis and intervention.
Scientific and industrial instruments · 1960
Scientific microscopes and industrial equipment
Olympus historically supplied research microscopes, industrial microscopes, nondestructive-testing equipment, and related precision instruments. These activities were transferred to Evident in 2022 and are therefore part of the brand’s historical scope rather than Olympus Corporation’s current core business.
Former scientific imaging products
Olympus microscopes and scientific instruments
Olympus historically supplied research microscopes, industrial microscopes, nondestructive-testing equipment and related precision instruments for education, routine laboratory work, life-science research and materials analysis. This scientific-imaging operation was rebranded Evident and sold to Bain Capital in 2023.

Controversies

2011
Olympus accounting and governance scandal
After CEO Michael Woodford questioned unusually large advisory payments and acquisition-related transactions, Olympus dismissed him. Investigations found that the company had concealed investment losses through complex arrangements. The affair led to arrests, criminal proceedings, management changes, investor scrutiny and extensive governance reform. Olympus later paid approximately US$646 million in fines related to the illegal accounting and kickback scheme. Olympus became embroiled in a major corporate scandal after former CEO Michael Woodford questioned unusual acquisitions and advisory payments. Subsequent investigations found that the company had concealed substantial investment losses through complex transactions. The episode caused the resignation of senior executives, legal and regulatory action, and a severe governance crisis. Olympus later undertook reforms to its board, internal controls, disclosure practices, and management structure.
Source

2018Global brand and corporate-philosophy rollout
Global
Olympus developed a common global purpose and five core values through workshops and a brand-ambassador program involving employees from multiple countries. The initiative supported the company’s transformation into a globally integrated medtech organization. Olympus developed a common global purpose and five core values through workshops and a brand-ambassador program involving employees from multiple countries. The initiative supported the company's transformation into a globally integrated medtech organization. The new framework was used in internal communications, leadership activities, recognition programs and business decision-making.
Outcome. The new framework was used in internal communications, leadership activities, recognition programs, and business decision-making.
Source
2013Endoscopy Day newspaper awareness campaign
Japan
Olympus used Japan’s July 14 Endoscopy Day to publish a national newspaper advertising package about the importance of endoscopic examination. The creative work used multiple small placements and a larger informational advertisement to make endoscopy less intimidating and encourage families to think about screening. Olympus used Japan's July 14 Endoscopy Day to publish a national newspaper advertising package about the importance of endoscopic examination. The creative work used multiple small placements and a larger informational advertisement to make endoscopy less intimidating and encourage families to think about screening. The campaign sought to improve public understanding of endoscopy and provide a prompt for readers to seek accurate information rather than rely on fears associated with older gastrocamera experiences.
Outcome. The campaign sought to improve public understanding of endoscopy and provide a prompt for readers to seek accurate information rather than rely on fears associated with older gastrocamera experiences.
Source
2012Olympus corporate television advertising with Aoi Miyazaki
Japan
Olympus resumed new corporate television advertising after a two-year interval and retained actor Aoi Miyazaki as its featured personality. Two advertisements used camera technologies, including five-axis stabilization and touch autofocus, to communicate the company's technical capabilities. The advertisements were scheduled for broadcast across ten Japanese regions through early January 2013.
Outcome. The advertisements were scheduled for broadcast across ten Japanese regions through early January 2013.
Source
2009PEN E-P1 launch campaign
Japan
Olympus marketed the PEN E-P1 to two groups: camera enthusiasts attracted by the revival of the PEN name and women and other consumers seeking a light, portable camera with serious image quality. The campaign presented Micro Four Thirds as a way to reduce camera size without abandoning interchangeable lenses. The product received strong support from both enthusiast and female consumer segments and was described as helping broaden the interchangeable-lens digital-camera market.
Outcome. The product received strong support from both enthusiast and female consumer segments and was described as helping broaden the interchangeable-lens digital-camera market.
Source

Brand decisions

2026
Agrees to acquire BioProtectM&A
Background
Olympus sought to strengthen urology and cancer-treatment solutions around its existing endoscopy and minimally invasive intervention businesses.
Action taken
Olympus agreed to acquire all issued shares of Israeli medical-device company BioProtect. BioProtect develops biodegradable balloon rectal spacers intended to protect healthy tissue during prostate-cancer radiation treatment.
Aftermath
The proposed acquisition would expand Olympus into prostate-cancer treatment support and add a new technology platform to its urology and oncology portfolio, subject to closing conditions.
Announced acquisition consideration. US$270 million (2026 announcement)
Source
2024
Collaboration with Canon Medical on endoscopic ultrasoundProduct launch
Background
Endoscopic ultrasound combines endoscopic access with ultrasound imaging and requires expertise in both fields.
Action taken
Olympus and Canon Medical agreed to collaborate on a jointly developed endoscopic ultrasound system.
Aftermath
As of 2025, the collaboration has not yet produced a commercial product, but represents a strategic move by Olympus to expand its presence in endoscopic ultrasound.
Source
2023
Divestment of EvidentM&A
Background
Olympus continued simplifying its portfolio around medical devices and endoscopy.
Action taken
The former scientific-solutions operation, operating as Evident, was sold to Bain Capital.
Aftermath
Olympus's direct portfolio was further concentrated on medical and surgical technologies.
Source
2023
Acquires Taewoong Medical to expand gastrointestinal interventionM&A
Background
Olympus identified gastrointestinal treatment devices, including stents and related products, as an opportunity to broaden the solutions available to patients with digestive diseases and cancer.
Action taken
The company announced an agreement to acquire South Korean device maker Taewoong Medical, with consideration consisting of an upfront payment and possible milestone payments.
Aftermath
The transaction was intended to add a wider gastrointestinal treatment portfolio and strengthen Olympus’s position in therapeutic endoscopy.
Maximum announced consideration. US$370 million (2023 announcement)
Source
2021
Acquisition of Medi-TateM&A
Background
Olympus sought to expand its minimally invasive urology portfolio.
Action taken
Olympus completed the acquisition of Israeli medical-device company Medi-Tate and its iTind technology.
Aftermath
The transaction broadened Olympus's offering for benign prostatic hyperplasia and lower urinary-tract symptoms.
Source
2021
Concentrates the group on medical technologyStrategy
Background
Olympus concluded that its diversified imaging, scientific, and medical structure did not best support its long-term growth objectives. Medical technology offered the strongest strategic fit with the company’s capabilities and global market position.
Action taken
The company transferred its imaging business to OM Digital Solutions and proceeded with the separation of its scientific business, later transferred to Evident.
Aftermath
Olympus became a substantially more focused medtech company centered on endoscopy, surgical intervention, and related treatment technologies.
Source
2021
Builds a technology-led medical M&A programM&A
Background
Olympus aimed to make therapeutic devices a second major growth pillar alongside endoscopy and to obtain specialized technologies more quickly through acquisitions.
Action taken
The company pursued multiple acquisitions, including Quest Photonic Devices for fluorescence imaging and Medi-Tate for urology, while also establishing a U.S. corporate venture-capital capability focused on emerging technologies.
Aftermath
The program broadened Olympus’s medical portfolio and reinforced a strategy of acquiring technologies that could be combined with its global clinical and commercial infrastructure.
Source
2020
Transfer of the imaging divisionM&A
Background
Olympus concluded that cameras and audio recorders were no longer central to its medical-technology strategy.
Action taken
The imaging division was transferred to OM Digital Solutions, with Japan Industrial Partners becoming its controlling backer.
Aftermath
Olympus became more narrowly focused on endoscopy and surgical technologies, while OM Digital Solutions continued the former camera business.
Source
2020
Acquires Veran Medical TechnologiesM&A
Background
Olympus sought to strengthen respiratory endoscopy and navigation-assisted examination capabilities.
Action taken
Its U.S. organization agreed to acquire Veran Medical Technologies, a company developing respiratory-endoscopy examination support systems.
Aftermath
The transaction added respiratory-focused technology and supported Olympus’s effort to develop treatment-device businesses alongside gastrointestinal endoscopy.
Announced acquisition consideration. US$340 million (2020 announcement)
Source
2012
Prioritize mirrorless imaging while seeking a Sony capital allianceStrategy
Background
Olympus faced pressure in consumer photography and discussed a strategic capital relationship with Sony.
Action taken
The companies announced a proposed capital and medical-technology partnership, while Olympus emphasized mirrorless interchangeable-lens cameras.
Aftermath
The medical relationship produced joint surgical-endoscopy development, while Olympus later exited direct camera operations.
Source

Recent events

2021-06-24
Olympus Provi CM20 wins 2021 Edison Award[20]Olympus Provi CM20 获得 2021 年爱迪生奖news-medical.net
Reported: 2021-06-25
Olympus announced that its OLYMPUS Provi CM20 incubation monitoring system won a Bronze Edison Award in the Cellular Research and Disease Prevention category.
2021-05-28
Olympus finalizes acquisition of Medi-Tate[21]奥林巴斯完成对Medi-Tate的收购finanznachrichten.de
Reported: 2021-05-28
Olympus announced that it had finalized its acquisition of Israeli medical device company Medi-Tate, adding Medi-Tate's iTind device to its portfolio.
2021-01-31
Olympus announces Olympus Continuum educational platform[22]Olympus宣布推出Olympus Continuum教育平台briefingwire.com
Olympus Corporation announced the launch of Olympus Continuum, a global educational platform offering healthcare professionals learning and training opportunities.
Unconfirmed
Olympus collaborates with Tokyo Medical and Dental University to test a digital data solution[23]Olympus 与东京医科齿科大学合作测试数字数据解决方案selectscience.net
Olympus is collaborating with Tokyo Medical and Dental University to test a cloud-based digital solution for archiving, organizing and sharing data from the Olympus CM20 incubation monitoring system. The article says researchers and Olympus engineers will refine the solution over the next year.
2020-12-03
Olympus signs patient-education partnership with COPD Foundation[24]Olympus 与 COPD Foundation 签署患者教育合作协议prnewswire.com
Reported: 2020-12-03
Olympus signed a partnership agreement with the COPD Foundation to support patient education about treatment options for severe emphysema. The partnership will provide endobronchial valve education throughout 2021.
Unconfirmed
Olympus acquires FH ORTHO[25]奥林巴斯收购 FH ORTHOselectscience.net
Olympus announced that it had acquired FH ORTHO SAS, an international orthopedic company headquartered in France. The article does not give the acquisition's completion date.
Unconfirmed
Olympus releases OM-D Webcam beta application[26]Olympus 发布 OM-D Webcam 测试版应用engadget.com
Reported: 2020-07-03
Olympus released a beta application called OM-D Webcam that gives select Olympus cameras webcam capabilities when connected to a PC via USB-C tether. It works only on Windows and is compatible with select camera models.
2020-07-02
Olympus releases beta webcam software for OM-D cameras[27]奥林巴斯为OM-D相机推出网络摄像头测试版软件amateurphotographer.com
Reported: 2020-07-02
Olympus announced free beta software that transforms select OM-D cameras into webcams for video conferencing and livestreaming; it is compatible with five camera models and Windows 10.
2020-06-24
Olympus announces planned transfer of its imaging business[28]奥林巴斯宣布计划转让映像业务tech.sina.com.cn
Reported: 2020-06-24
Olympus and Japan Industrial Partners signed an agreement confirming their intention to transfer Olympus's imaging business, with completion planned by the end of 2020.
2020-06-24
Olympus announces plan to transfer its camera business to JIP[29]奥林巴斯宣布计划将相机业务转让给JIPindiatoday.in
Reported: 2020-06-25
Olympus confirmed that it was selling its camera business to Japan Industrial Partners (JIP) and said the companies planned to sign a definitive agreement by the end of 2020.

Showing the 10 most recent.

Sources35 sources

Cite this profile: Cite the canonical profile. /brand-wiki/olympus-corporation · Editorial policy · How profiles are compiled